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We have recently shown that the G protein-coupled recep-
tor 55 (GPR55) mediates intracellular effects of cannabi-
noids and other, non-cannabionid, ligands in addition to
the classical cannabinoid 1 (CB1R) and 2 (CB2R) recep-
tors. Here we show that the presence of either CB1R or
CB2R alters the signaling pathways of GPR55. HEK-293
cells stably expressing either the GPR55 receptor alone or
in combination with either CB1 (CB1/GPR55) or CB2
(CB2/GPR55) receptors were characterized in terms of sig-
naling and receptor trafficking properties. To this end,
FLEX calcium release, reporter gene and antibody feeding
assays have been performed. Here we show that GPR55 is
activated by lysophosphatidylinositol (LPI) and couples
to Gα13, which in turn activates RhoA and RhoA kinase
(ROCK). Moreover, we discovered that GPR55 activation
leads to an efficient activation and nuclear translocation
of nuclear factor of activated T-cells (NFAT) transcription
factor family. We next tested a panel of known cannabi-
noid ligands and discovered that GPR55 is activated by
AM251, which is a known inverse agonist on the CB1R. In
addition, the CB1R antagonist SR141716A (rimonabant)
was able to induce GPR55-mediated signaling, although it
was less potent than both AM251 and LPI. LPI was also
able to induce the internalization of GPR55. Lastly, we
found that CB1R and CB2R co-localize with GPR55 on the
surface of HEK cells and also can block the NFAT activa-
tion mediated by GPR55.
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